Contract Development Manufacturing Organization (CDMO)
GenIbet shareholders include Instituto de Biologia Experimental e Tecnológica (iBET) and leading Portuguese companies in the Pharma and Food industries. One of the major drivers for the creation of GenIbet was the perception of its main shareholder, iBET, of client needs and desires to pursue development work into a GMP environment. The first market approached was the Bacterial market and GenIbet was certified in June 2009 in a joint project with Novartis Institute for Global Health (at present GVGH) for the manufacture of a Typhoid Fever Vaccine. The work performed included the manufacture of the master and working cell banks, as well as one of the vaccine components.
GenIbet has expanded its production units and activities since them and the entire facility which currently comprises 3 independent manufacturing units (2 Class C, 1 Class B all BSL2) is dully qualified since 2014 by the Portuguese regulatory authorities (Infarmed) for biopharmaceuticals production and manufacture of Investigational Medicinal Products (IMPs).
More products from Genibet Biopharmaceuticals
GenIbet runs projects covering a broad spectra of Biopharmaceuticals development, including Recombinant proteins, Vaccines, RNA, Live Microbial Products and Cell and Gene Therapy products. GenIbet has experience with mammalian, avian and insect cells (A549, CAP, CHO, EB66, HEK293, SF9, MDCK, Vero), Bacteria a...More info
WebsiteView all contact information
Are you a supplier?
Here's what CPhI Online can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation